FDA grants Priority Review for Insmed’s ARIKAYCE sNDA; PDUFA Jan. 28, 2027

Insmed said the FDA granted Priority Review for its ARIKAYCE sNDA for MAC lung disease, with a PDUFA date of Jan. 28, 2027. Roth Capital cut its price target on INSM from $212 to $198.